Current Students

Back row left to right: Matt Jones, Chen Khuan Wong, Carly Garrison, Keri Dame, and Elyse Kozlowski. Front row left to right: Andy Hoss, Shoumita Dasgupta, Hila Milo Rasouly, Dana Lau Corona, Sarah Kleinsorge, Akshaya Ramesh, and  Barry Horne. *Shoumita Dasgupta and Matthew Jones are the Directors of the Program

Back row left to right: Matt Jones, Chen Khuan Wong, Carly Garrison, Keri Dame, and Elyse Kozlowski. Front row left to right: Andy Hoss (’15), Shoumita Dasgupta, Hila Milo Rasouly (’15), Dana Lau Corona, Sarah Kleinsorge (’15), Akshaya Ramesh, and Barry Horne.
*Shoumita Dasgupta and Matthew Jones are the Directors of the Program

The students of the GPGG are a diverse group.  Each has a strong background in research and helps support the strong community and learning environment.

Stefanie Chan (Petrocca Lab)
Stefanie is a second-year GPGG PhD student with the Petrocca laboratory in the department of Surgical Research. The Petrocca laboratory is currently focused on advancing precision medicine therapies for triple-negative breast cancer (TNBC; the most aggressive subtype of breast cancer) into clinical testing. The primary goal of this program is to identify selective vulnerabilities linked to defined genetic and epigenetic states in distinct TNBC subtypes, and prioritize the highest-value targets for downstream drug development in select subgroups of TNBC patients. The lab is also interested in dissecting the molecular basis behind TNBC’s exceptional response and resistance to clinically available drugs, particularly 2nd-generation proteasome inhibitors and nuclear export drugs.

Dana Lau Corona (Waxman Lab)
Dana is a fifth-year PhD student in Dr. David Waxman’s lab. Her research project focuses on the hormonal regulation of sex-differential gene expression in the liver. These sex-biased gene profiles have been linked to clinically relevant sex differences in drug metabolism and cardiovascular disease risk.  She uses mouse models and next-generation sequencing (RNA-seq, ChIP-seq and DNAse-seq) to elucidate the transcriptional and epigenetic networks that dictate sex-differential gene expression in the liver.

Keri Dame (Ikonomou Lab)
Keri is a third-year GPGG PhD student with the Ikonomou laboratory in the Pulmonary Center / Center for Regenerative Medicine (CReM).  Her main research revolves around lung development – in vivo processes as well as in vitro specification of lung progenitors from mouse stem cells using directed differentiation.

Carly Garrison (Spira Lab)
Carly’s research focuses on the regulatory role of microRNAs in lung diseases, specifically in IPF and lung cancer. In IPF we have identified microRNA isomirs that have the ability to target genes outside of those targeted by the canonical form of the microRNA, highlighting the diverse nature of microRNAs and microRNA editing. In lung cancer, there are two distinct projects, one on a previously identified microRNA and another on a never smoker lung adenocarcinoma specific microRNA. miR-4423 is a microRNA that was previously identified in the Spira/Lenburg lab as being able to suppress lung cancer and as a regulator of normal lung airway epithelium. Current research is being performed to uncover the mechanism of action with which miR-4423 modulates these phenotypes. In never smoker lung adenocarcinoma we have identified a microRNA that is only differentially expressed in never smokers and has the potential to regulate an extensive number of mRNA by direct and indirect actions. Our work on identifying microRNAs in lung disease may eventually lead to novel therapeutic microRNA targets, an area that is quickly gaining momentum.

Barry Horne (Bonegio Lab)
Barry is a third-year GPGG PhD student in the Bonegio laboratory. His long-term interest is in performing translational research that focuses on the genetic causes of autoimmune diseases, with an ultimate goal of working towards better treatments and/or cures for autoimmune disorders such as Lupus and Anti-Phospholipid Syndrome (APS). The Bonegio lab is investigating various potential genetic causes and therapies for Lupus – particularly in the context of Lupus Nephritis. Barry is currently examining the possible roles of several different genes in “Immune-Complex Glomerulo-Nephritis” (IC-GN) induced proteinuria in mice. The goal of this research is to discover and define the genetic differences and signaling pathway(s) that lead to that disease state, in order to then develop ways to target them therapeutically in humans.

Elyse Kozlowski (Jones Lab)
Elyse’s research focuses on how immune cells can post-transcriptionally regulate cytokine expression in response to bacterial pneumonia. It centers on how certain enzymes called TUTases (such as Zcchc11 and Zcchc6) can regulate gene expression by modifying microRNAs, which prevents them from binding to their target mRNAs. Uridylation of microRNAs may be one way immune cells can fine tune cytokine expression to promote host defense while preventing tissue injury during pneumonia.

Akshaya Ramesh (Kepler Lab)
Akshaya is a fourth-year graduate student in the Genetics and Genomics program and works in Dr. Thomas Kepler’s lab in the Department of Microbiology. Her research primarily focuses on understanding the immunogenetics of rhesus macaque monkeys, which are currently used as animal models for HIV research. As part of her thesis project she will work on assembling the whole genome (WGS) of the rhesus macaque from one monkey and generate high-resolution immunoglobulin loci sequence information from nine additional macaques. This information will serve as a valuable reference while studying potential vaccine candidates to identify mutations that make them especially potent. In addition to this, the WGS of the rhesus macaque will open a new suite of tools in macaque biology and have far reaching impacts considering that these monkeys are used extensively in biomedical research.

Chen Khuan Wong (Thiagalingam Lab)
Chen’s research focuses on studying the association between Smad4 defect and metastasis, a major cause of cancer death, in colon cancer.  Smad4 is a tumor suppressor which localizes to 18q, a chromosomal region with frequent loss of heterozygosity in advanced disease stage.  Smad4 plays a central role in the TGF-beta antigrowth signaling pathway and its loss of function is associated withpoor prognosis and chemotherapeutic resistance in colon cancer.  Currently, I am working on identifying Smad4 interacting transcription factors and cofactors, which may serve as targets that become alternatively inactivated, culminating in loss of metastasis suppression.